300942 易瑞生物
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)0.2701.993-20.3888.68931.665
总资产报酬率 ROA (%)0.1631.217-14.0156.81426.200
投入资产回报率 ROIC (%)0.1741.316-15.4777.65929.590

边际利润分析
销售毛利率 (%)64.46670.62849.92956.50671.632
营业利润率 (%)0.4219.349-68.98714.28344.897
息税前利润/营业总收入 (%)2.86012.285-71.06912.57745.693
净利润/营业总收入 (%)1.7297.411-72.79812.03439.574

收益指标分析
经营活动净收益/利润总额(%)-105.14570.94544.059138.51192.300
价值变动净收益/利润总额(%)-95.801-20.20530.4192.8203.606
营业外收支净额/利润总额(%)28.698-6.4801.404-3.395-0.089

偿债能力分析
流动比率 (X)6.4144.9465.3873.3765.731
速动比率 (X)5.9334.6805.1582.8725.132
资产负债率 (%)39.06240.27837.42524.77717.869
带息债务/全部投入资本 (%)34.56935.66629.32710.9621.914
股东权益/带息债务 (%)187.645178.619234.117763.4644,870.858
股东权益/负债合计 (%)155.821148.061167.253303.659458.756
利息保障倍数 (X)1.2603.50564.635-10.16754.695

营运能力分析
应收账款周转天数 (天)151.517136.622113.35747.41248.002
存货周转天数 (天)215.857196.462186.842117.164165.069